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Abstract
We compared the effects of monotherapy (photodynamic
therapy or chemotherapy) versus combination therapy
(photodynamic therapy plus a specific drug) on the non–
small cell lung cancer cell line H1299. Our aim was to
evaluate whether the additive/synergistic effects of
combination treatment were such that the cytostatic dose
could be reduced without affecting treatment efficacy.
Photodynamic therapy was done by irradiating Photofrin-
preloaded H1299 p53/p16-null cells with a halogen lamp
equipped with a bandpass filter. The cytotoxic drugs used
were cis-diammine-dichloroplatinum [II] (CDDP or cisplatin)
and 2V,2V-difluoro-2V-deoxycytidine (gemcitabine). Vari-
ous treatment combinations yielded therapeutic effects
(trypan blue dye exclusion test) ranging from additive to
clearly synergistic, the most effective being a combination
of photodynamic therapy and CDDP. To gain insight into
the cellular response mechanisms underlying favorable
outcomes, we analyzed the H1299 cell cycle profiles and
the expression patterns of several key proteins after
monotherapy. In our conditions, we found that photody-
namic therapy with Photofrin targeted G0-G1 cells, thereby
causing cells to accumulate in S phase. In contrast, low-
dose CDDP killed cells in S phase, thereby causing an
accumulation of G0-G1 cells (and increased p21 expres-
sion). Like photodynamic therapy, low-dose gemcitabine
targeted G0-G1 cells, which caused a massive accumula-
tion of cells in S phase (and increased cyclin A expression).
Although we observed therapeutic reinforcement with
both drugs and photodynamic therapy, reinforcement was
more pronounced when the drug (CDDP) and photody-
namic therapy exert disjointed phase-related cytotoxic
activity. Thus, if photodynamic therapy is appropriately
tuned, the dose of the cytostatic drug can be reduced
without compromising the therapeutic response. [Mol
Cancer Ther 2006;5(3):776–85]
Introduction
Although chemotherapy is the leading treatment for most
types and stages of cancers, photodynamic therapy is an
effective anticancer procedure for selected tumors (1). This
procedure involves administration of a tumor-localizing
photosensitizing agent that when activated by light of a
specific wavelength mediates cell destruction via the
production of singlet oxygen. Photodynamic therapy has
been shown to have few or no side effects in patients with
Barrett’s esophagus (high-grade dysplasia and early carci-
noma) and in selected cases of early squamous cell
carcinoma (2). One of the most widely used photosensitiz-
ing drugs is the hematoporphyrin-derivative Photofrin.
This nontoxic substance has been used for photodynamic
therapy for f8 years and is the only one widely approved
for human therapy. On exposure of Photofrin-loaded cells
to visible light, intracellular toxic oxygen species (singlet
oxygen, 1O2) are generated that can trigger cell apoptosis or
necrosis (3, 4).
Anticancer drugs target several cellular components and
activate responses that go from cell repair to cell death.
However, chemotherapy is effective only at high doses,
because, at low doses, tumor cells may repair damage and
resume their original high proliferation rate (5). Cis-
diammine-dichloroplatinum [II] (CDDP or cisplatin) and
2V,2V-difluoro-2V-deoxycytidine (gemcitabine) are widely
used in the management of various cancers. By forming
adducts in DNA, CDDP inhibits DNA replication and chain
elongation, which accounts for its antineoplastic activity. In
clinical practice, CDDP is often combined with other drugs.
Synergy between CDDP and other chemotherapeutic
agents occurs by various pathways: increased intracellular
drug accumulation, enhanced binding to DNA, and
decreased DNA repair (6). Gemcitabine is a deoxycytidine
analogue that is effective against solid tumors, including
non–small cell lung cancer. After transport into the cell,
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gemcitabine requires phosphorylation by deoxycytidine
kinase to exert biological activity (7, 8). The enzyme
responsible for this reaction is also the rate-limiting step
in gemcitabine activation (8). It has been suggested that
the combination of photodynamic therapy and convention-
al cancer treatments may become a workable anticancer
strategy (9).
The aim of our study was to identify photodynamic
therapy/chemotherapy combinations in which the dose of
the most toxic compound could be decreased without a loss
of efficacy. To this aim, we examined the response of H1299
human lung metastatic non–small cell lung cancer cells
(cell viability, cell cycle, and protein expression) to
moderately toxic doses of CDDP or gemcitabine with
Photofrin/photodynamic therapy, administered separately
and in appropriate combinations.
Materials andMethods
Cell Cultures
The NCI-H1299 human non–small cell lung cancer cell
line was obtained from American Type Culture Collection
(Rockville, MD). They were cultured in RPMI 1640, 2
mmol/L L-glutamine, 10 mmol/L HEPES, 1 mmol/L
sodium pyruvate, 4,500 mg/L glucose, 1,500 mg/L sodium
bicarbonate, 100 Ag/mL streptomycin, 100 units/mL peni-
cillin, and 10% FCS. The medium was changed every 3 days.
All media and cell culture reagents were purchased from
Life Technologies (San Giuliano Milanese, Italy). NCI-H1299
cells are p53/ and p16/. All treatments, individual
and in combination, were done in triplicate samples in tissue
culture dishes (35 mm) in which 5  104 cells were routinely
seeded. A larger number of cells (4  105) were seeded for
cell cycle measurements and for protein extraction for
Western blotting purposes. The effects of monotherapy with
drugs or photodynamic therapy or combined therapy (drugs
+ photodynamic therapy) were evaluated (a) by trypan blue
assays (to check residual cell viability), (b) by analyzing cell
cycle profiles (to determine the cell distribution in the
various conditions), and (c) by analyzing expression patterns
(Western blots) of specific proteins involved in the control of
cell growth and survival.
Cytotoxic Drugs
CDDP was obtained from Sigma-Aldrich Srl (Milan,
Italy). A stock solution was obtained by dissolving CDDP
in DMSO to obtain a final concentration of 40 mmol/L.
Aliquots were stored at 20jC until used. Gemcitabine
chlorhydrate (Gemzar) was supplied as dry powder by
Eli Lilly SpA (Sesto Fiorentino, Italy). A stock solution
(67 mmol/L) was obtained by dissolving gemcitabine in an
isotonic solution (0.9% NaCl). Aliquots were stored at
20jC until used.
Photosensitizer
The Photofrin (the hematoporphyrin derivative Porfimer
sodium) used in this work was supplied as freeze-dried
powder (lot no. 162A6-06; Axcan Pharma, Mont-Saint-
Hilaire, Quebec, Canada). Its absorption spectrum consists
of various peaks within the visible region. A Photofrin
stock solution was obtained by dissolving the powder in
water containing 5% glucose to obtain a final concentration
of 2.5 mg/mL. This solution was stored in aliquots at
20jC in the dark. Before measurements, appropriate
aliquots of this solution were diluted to the desired
concentration. Except for ‘‘dark toxicity assays,’’ Photofrin
was always used at a concentration of 2.5 Ag/mL. All
treatments involving Photofrin were done on triplicate.
Cells were exposed to 2.5 Ag/mL Photofrin for 16 hours
before irradiation.
Chemotherapy and Chemotherapy Schedule
Usually, 5  104 H1299 cells were seeded in 35-mm tissue
culture dishes and exposed to the cytotoxic substances
(individual or combined with photodynamic therapy) 24
hours later. This procedure was carried out in triplicate.
Normally, 4  105 cells were used for cell cycle measure-
ments and protein extraction for Western blotting. To
obtain CDDP/gemcitabine dose-response curves, culture
dishes were treated with CDDP (2.5–12 Amol/L) or
gemcitabine (2–12 nmol/L) and kept at 37jC for 24 hours.
After incubation, cells were washed and released into fresh
medium. Cell viability was evaluated with the trypan blue
assay (as detailed in ref. 10) 24 hours later, counting
between 15 and 30 cells per field. Two sets of data were
collected for each drug. In combination experiments, after
incubation with the drug (0–24 hours) and Photofrin (8–24
hours), cells were washed, placed in a colorless saline
solution (Hank’s), and immediately irradiated. After
irradiation, cells were placed in fresh complete medium,
and cells negative to trypan blue staining were counted 24
hours later (see Fig. 1). Residual viability was expressed as
percentage of trypan blue–negative cells versus untreated
controls.
PhotodynamicTherapy and Photodynamic Therapy
Schedule
Cells were irradiated by a broadband light delivered with
a PTL-Penta apparatus (Teclas, Sorengo, Switzerland). This
apparatus consists of a halogen lamp (Osram 250 W, 24 V
Osram, Munich, Germany) equipped with a bandpass filter
(>80% transmittance in the 510 to 590 nm spectral region;
bandwidth f40 nm at 50% of the peak) corresponding
approximately to one of the Photofrin absorption peaks.
The emission spectrum was measured with a Macam
SR9910 spectroradiometer (Macam Photometrics, Living-
ston, Scotland, United Kingdom). The light was delivered
through an 8-mm bundle of optical fibers placed at a
distance from the cell plates that ensures uniform illumi-
nation of the entire cell monolayer. The fluence rate at the
level of the cell monolayer was fixed at 6 mW/cm2 and
irradiations were done with light doses of up to 1.8 J/cm2.
We invariably used a Photofrin concentration of 2.5 Ag/mL.
At a fluence of 0.54 J/cm2, photodynamic therapy mono-
therapy reduced H1299 cell viability to f50% that of
treated but not irradiated cells (controls). Doses between
0.18 and 0.54 J/cm2 were used in the combination experi-
ments. Because only a few cells survived combined therapy
with fluences >0.54 J/cm2, higher fluences were not
considered. In brief, after incubation, cells were washed
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extensively, placed in colorless Hank’s solution, exposed to
light, and analyzed by cytofluorimetry either immediately
or after exposure to fresh medium for a further 24 hours.
Similarly, cell extracts obtained f3 or 24 hours after
irradiation were used to obtain protein profiles (Western
blots). Residual cell viability was assessed by trypan blue
assay after cells have been placed in fresh medium for 24
hours (Fig. 1).
Flow Cytometry
Dishes (10 cm) containing 4  105 H1299 cells were
incubated for 24 hours at 37jC in 7 mL complete medium
(controls) or in medium supplemented with Photofrin (2.5
Ag/mL) alone or associated with CDDP (2.5 Amol/L) or
gemcitabine (4 nmol/L). Cells were exposed to photody-
namic therapy as described above and were then detached
from the dishes by trypsinization, suspended in serum-
rich medium, centrifuged, washed twice with 1 mL PBS,
and resuspended for storage (20jC) in 95% ethanol.
Before analysis, fixed cells were washed twice, centri-
fuged, and resuspended in 1 mL PBS containing 1 Ag
RNase and 100 Ag propidium iodide (11). Samples were
stored in the dark for 20 minutes at room temperature
before final readings. The cellular orange fluorescence of
propidium iodide was detected in a linear scale using a
flow cytometer (FACScan, Becton Dickinson, Mountain
View, CA) equipped with an excitation laser line at 488
nm. About 30,000 events (i.e., fluorescence readings,
corresponding to not less than 20,000 cells) were recorded
for each sample. The cell cycle was examined after
monotherapy and combined treatment at the indicated
times (see Fig. 1). Data were analyzed with ModFit/LT
(Verity Software, Topsham, ME).
Median Effect Analysis
We used the median effect analysis (12) together with the
combination index (CI) to ascertain synergy and the
additivity/antagonism of photodynamic therapy and che-
motherapy. The median effect analysis derives directly
from the mass action law and does not depend on a
reaction mechanism. The reference equation is Fa / Fu =
(D / Dm) * m , where Fa is the affected fraction, Fu is the
unaffected fraction, D is the dose, Dm is the median dose
(50%, for instance), and m is a coefficient related to the
shape of the dose-response curve (m = 1, hyperbolic; m > 1,
sigmoidal; m < 1, negatively sigmoidal). The shape is easily
determined from the dose-effect curve from which Dm is
directly estimated. The CI for treatments that are not
mutually exclusive (i.e., that unequivocally have different
modes of action) can be calculated by (13): CI = (D)1 / (Dx)1
+ (D)2 / (Dx)2 + [(D)1(D)2] / [(Dx)1(Dx)2], in which (D)n is
the dose of the nth drug (or of light) needed to obtain a
given effect in the combination and (Dx)n is the dose of the
same drug (or light) necessary to obtain the same effect
when used alone. Chou and Talalay (12) defined synergism
as a more than expected additive effect, where the additive
effect is designated CI equal to unity. Thus, for mutually
exclusive agents that have totally independent modes of
action, CI < 1, CI = 1, and CI > 1 indicate synergy, additive
effect, and antagonism, respectively. We thus constructed
several dose-response curves at a constant fluence and at a
constant drug concentration.
Western Blot Analysis
Total cell protein preparations were obtained by lysing
cells in 50 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, 1%
NP40, 0.1% Triton, 2 mmol/L EDTA, 10 Ag/mL aprotinin,
and 100 Ag/mL phenylmethylsulfonyl fluoride. Protein
concentration was routinely measured with the Bio-Rad
protein assay (14). Polyacrylamide gels (10–15%) were
prepared essentially as described by Laemmli (15). Molec-
ular weight standards were from New England Biolabs
(Beverly, MA). Proteins separated on the polyacrylamide
gels were blotted onto nitrocellulose filters (Hybond-C
pure, Amersham Italia, Milan, Italy). Filters were washed
and stained with specific primary antibodies and then with
secondary antisera conjugated with horseradish peroxidase
(Bio-Rad; diluted 1:2,000). Filters were developed using an
electrochemiluminescent Western blotting detection
reagent (Amersham Italia) and quantified by scanning
with a Discover Pharmacia scanner equipped with a Sun
Spark Classic Workstation. The anti-Bcl-2 (100), Bcl-XL
(S-18), Bax (N-20), p21 Cip1 (C-19), cyclin A (C-19), Cdk2
(M2), HSP60 (N-20), HSP70 (K-20), and actin (C-2) anti-
bodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-caspase-3 (Ab-3), human (mouse), was from
Calbiochem (San Diego, CA).
Results and Discussion
The metastatic non–small cell lung cancer H1299 carcino-
ma cell line does not express p53 or p16 INK4a. Although
sensitivity to photodynamic therapy is not altered in
human tumor cells after p53 abrogation (16), inactivation
of the p53 and p16 INK4a pathways does not completely
abrogate stress responses in carcinoma cells (17).
We evaluated if Photofrin/photodynamic therapy plus
CDDP or gemcitabine induces an additive or even a
synergistic effect, our aim being to determine whether the
Figure 1. Single-agent and combination treatment schedule. For single-
agent CDDP or gemcitabine treatments, cells were incubated with
chemotherapeutic drugs for 8, 12, or 24 h, washed, and analyzed
immediately and after 3 h. Cells exposed to drugs for 24 h were also
analyzed 24 h after washing and release into fresh medium. Before
photodynamic therapy, cells were incubated for 16 h with Photofrin in the
dark. For combination treatments, cells were treated with CDDP or
gemcitabine at prefixed concentrations, and Photofrin was added 8 h later.
The samples were washed and analyzed immediately or released in fresh
medium and analyzed 24 h later. CC, cell cycle; WB, Western blot; TBa,
trypan blue assay; star, light turned on.
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dose of the cytostatic drug can be reduced. To identify the
most effective doses of the components of combination
therapy, we analyzed (a) the response of Photofrin-treated
H1299 cells to increasing light doses, (b) the response of
cells to increasing concentrations of CDDP or gemcitabine,
and (c) the response of cells to combined therapy in
selected conditions.
We first tested low CDDP (V2.5 Amol/L) and gemcitabine
(between 2 and 8 nmol/L) concentrations and mild
photodynamic therapy conditions (Photofrin concentration,
2.5 Ag/mL; light fluence, 0.18–0.54 J/cm2). However, we
focused on a concentration of 2.5 Amol/L for CDDP and
4 nmol/L for gemcitabine, and the fluence of choice was
0.54 J/cm2. These drug concentrations caused a near
50% mortality when used alone. Higher concentrations
(>5 Amol/L CDDP or >8 nmol/L gemcitabine) were not
compatible with photodynamic therapy at a fluence of 0.54
J/cm2, because no (CDDP) or only a few cells (gemcitabine)
survived this combined treatment. Fluctuations of the
lamp, which make it difficult to measure fluence accurately
within the short irradiation time (<30 seconds), precluded
the use of lower fluences (<0.2 J/cm2).
We evaluated Photofrin-induced toxicity in the absence
of light (‘‘dark toxicity’’) in 5  104 cells seeded in 35-mm
tissue culture dishes and treated 24 hours later with 0, 2.5,
4, 8, 10, and 25 Ag/mL Photofrin. Sixteen hours later, cell
viability was evaluated by the trypan blue and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays (data not shown). We compared the viability of
normally growing cells (100%) versus Photofrin-treated but
not light-sensitized cells. Cell viability decreased in a dose-
dependent fashion starting with 3.0 Ag/mL Photofrin, and
25 Ag/mL Photofrin reduced cell viability by a factor >5.
With 2.5 Ag/mL Photofrin, toxicity did not exceed 5%;
hence, we used this dose in the photodynamic therapy
experiments.
IndividualTreatments
Because photodynamic therapy was applied to cells
treated for 24 hours with CDDP or gemcitabine, we first
determined the cycle stage of cells on irradiation. To this
end, we incubated H1299 cells with 4 nmol/L gemcitabine
or 2.5 Amol/L CDDP for 0 (controls), 8, 12, and 24 hours.
The cells were then washed and immediately fixed for
cytofluorimetry. Gemcitabine rapidly induced depletion of
G2-M cells and hence an accumulation of G1 cells; 12 hours
later, almost all cells were in S phase (Table 1). Therefore,
when photodynamic therapy was applied, gemcitabine-
exposed (4 nmol/L) cells were mostly in S phase. CDDP,
on the contrary, caused cell accumulation in S phase
followed by cell synchronization in G1. Therefore, on
photodynamic therapy, the S and G2-M phases were
partially emptied. After cells were withdrawn from CDDP-
or gemcitabine-containing medium and placed in complete
medium, they reentered the normal cycle within 24 hours
(see also Fig. 1).
The two cytostatic drugs dose-dependently affected cell
viability (Fig. 2). At 2.5 Amol/L, CDDP reduced cell via-
bility byf50% versus controls, and with 12 Amol/L CDDP,
cell viability approached 0. Similarly, 4 nmol/L gemcita-
bine reduced cell viability by f50%, and 10 nmol/L
gemcitabine reduced it to <20% of control values. Cell
viability was not completely abolished even at much higher
gemcitabine concentrations (data not shown).
The photodynamic therapy experiments were done in
triplicate with 5  104 H1299 cells seeded in 35-mm tissue
culture dishes. Twenty-four hours after seeding, the cells
were incubated with Photofrin (2.5 Ag/mL) for 16 hours,
washed thrice with HBSS, and irradiated with increasing
doses of light (see below). Cells were released into drug-
free complete medium and left to grow forf3 or 24 hours.
At nontoxic Photofrin concentrations (i.e., 2.5 Ag/mL),
photodynamic therapy dose-dependently affected the
magnitude of cell injury (Fig. 3). When light fluence
increased from 0 to f1.40 J/cm2, cell viability decreased
proportionally. No cells survived a fluence of 1.80 J/cm2
(data not shown). At 0.54 J/cm2, cell viability was reduced
by f50%. We used this sublethal dose in combination
experiments with cytotoxic drugs. Unless indicated other-
wise, all experiments reported hereafter were conducted
with cells incubated for 16 hours with 2.5 Ag/mL Photofrin
and irradiated with a light fluence of 0.54 J/cm2.
Combined Effects
Because we aimed at using the lowest drug concentration
possible, we tested CDDP concentrations between 0.5 and
2.5 Amol/L and gemcitabine concentrations between 2 and
8 nmol/L while maintaining fluence at 0.54 J/cm2. Very
few cells treated with low concentrations of CDDP or
gemcitabine survived fluences above 0.54 J/cm2. Howev-
er, within the concentration range tested, gemcitabine did
not kill all H1299 cells (Fig. 2). Thus, for gemcitabine,
we evaluated the effects caused by a fixed fluence on
cells incubated with drug concentrations between 2 and
8 nmol/L and the effects caused by fixed drug concen-
trations (i.e., 4 and 8 nmol/L) and light fluences of 0.18,
0.28, 0.36, and 0.54 J/cm2. We evaluated the efficacy of
combined therapy by calculating the CI as detailed in the
next paragraph and as reported in Table 2A (fixed fluence,
0.54 J/cm2; CDDP between 0.25 and 2.50 Amol/L), Table 2B
(fixed fluence, 0.28 J/cm2; gemcitabine between 2 and
8 nmol/L), and Table 2C (fluence between 0.18 and 0.54
J/cm2, gemcitabine 4 nmol/L). The most striking results
were obtained with a light fluence of 0.54 J/cm2 combined
Table 1. Cytofluorimetric profiles of H1299 cells at 0 and 8, 12,
and 24 hours of treatment with CDDP (2.5 Mmol/L) or
gemcitabine (4 nmol/L)
Phase Control CDDP (2.5 Amol/L) Gemcitabine (4 nmol/L)
0 h 8 h 12 h 24 h 8 h 12 h 24 h
G0-G1 47.3 40.2 39.0 64.9 57.6 56.5 18.1
S 39.4 51.0 51.3 28.5 42.4 43.4 81.9
G2-M 13.3 8.8 9.7 6.6 0 0.1 0
NOTE: Values are expressed as percent. Note the specific effects at 24 hours
(bold).
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with 2.5 Amol/L CDDP or 4 nmol/L gemcitabine.
Individually, photodynamic therapy, CDDP, and gemci-
tabine reduced cell viability to 50 F 7%, whereas
photodynamic therapy combined with CDDP or gemcita-
bine reduced cell viability to 8 F 2% and 14 F 4%,
respectively (Fig. 4).
Median Effect Analysis
Using the Chou and Talalay method (12) and the equa-
tions developed by Mack et al. (13), we calculated the CI and
show that the effects of combined therapy at a fixed light
fluence (0.54 J/cm2) are additive within the range of CDDP
concentrations used. These effects changed from possibly
synergistic to explicitly synergistic at CDDP concentrations
above 2.0 Amol/L (Table 2A). Differently, the overall effect
remained additive with gemcitabine plus photodynamic
therapy. The CI was 1 both when the drug was increased
from 2 to 8 nmol/L and the light fluence was fixed at 0.28 J/
cm2 (Table 2B) and with gemcitabine fixed at 4 nmol/L and
light fluences were between 0.18 and 0.54 J/cm2 (Table 2C).
Cell Cycle and Protein Expression
To investigate the mechanisms by which Photofrin/
photodynamic therapy and the cytotoxic drugs exert their
effects when used alone or in combination, we analyzed
the H1299 cell cycle and the expression levels of the Bcl-2,
Bcl-XL, Bax, caspase-3, p21, pRb, cyclin A, Cdk2, HSP60,
and HSP70 proteins (Fig. 5), which are related to apoptosis,
cell cycle, and stress. Figure 1 shows the schedules of
single-agent and combination treatments. The cytofluori-
metric profiles obtained after the release of cells in drug-
free medium for an additional 24 hours represents the
distribution that would be found in the event of ineffective
photodynamic therapy.
CDDP. Using cytofluorimetry, we examined the H1299
cell cycle after 0, 8, 12, and 24 hours of incubation with
2.5 Amol/L CDDP (Table 1). After 24 hours, cells have accu-
mulated in G0-G1 phase (see Table 1; Fig. 6) with a conse-
quent loss of cells (f50%; trypan blue assay) in S phase.
After exposure to CDDP for 24 hours, cells were released
into fresh medium forf3 and 24 hours. Synchronization in
S phase was sustained for the first 3 hours, whereas cells
approached the normal cycle at 24 hours (data not shown).
This observation implies that the arrest in S phase was
reversible. Protein expression studies (Western blot) support
this notion. In fact, p21 protein expression was enhanced
in H1299 cells exposed to 2.5 Amol/L CDDP for 24 hours
(Fig. 5A, lane 2). However, p21 expression returned to basal
levels within 24 hours (Fig. 5A, lane 5).
Surprisingly, although H1299 cells are p53 mutated
(/), p21 protein expression seemed to be up-regulated
at transcriptional level in the presence of CDDP. However,
the p21 gene is also regulated by p53-independent factors,
including growth promotion factors and differentiation-
associated transcription factors (18). Moreover, CDDP
concentration and incubation conditions may account for
cytofluorimetric profile changes in various cells. In fact,
whereas high CDDP concentrations cause cells to accumu-
late in the S-G2 phases (13, 19–21), low CDDP doses induce
Figure 2. Effect of increasing concentrations of CDDP (bottom curve ;
0–15 Amol/L) and gemcitabine (top curve ; 0–12 nmol/L) on the viability
of H1299 cells. Two sets of data from separate experiments are reported.
Cells were incubated at the indicated CDDP or gemcitabine concentrations
for 24 h, washed, and incubated for 24 h in fresh medium. Cell viability
was measured by counting cells negative to trypan staining. Residual
viability was expressed as percentage of untreated cells (controls).
Triangles and diamonds, CDDP; squares and circles, gemcitabine.
Points, average of three determinations; bars, SD.
Figure 3. H1299 cells were incubated in the dark for 16 h with Photofrin
(2.5, 4.0, 8, or 10 Ag/mL). Dark toxicity was low (<5%) with 2.5 Ag/mL
Photofrin and high with 4 to 10 Ag/mL (circles ). Cell viability on irradiation
was measured by the trypan blue exclusion test with a Photofrin
concentration of 2.5 Ag/mL. Points, average of three determinations;
bars, SD. PDT, photodynamic therapy.
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an increase in p21 expression unaccompanied by bromo-
deoxyuridine incorporation (21), which suggests an arrest
in G1. A G1 arrest has also been reported in other cell lines
at high CDDP concentrations (50 Amol/L) but with short-
term (2 hours) exposure (22). Also in our hands, 24-hour
incubation with CDDP concentrations as high as 8 Amol/L
caused cells to accumulate in G2 (from <14% at 2.5 Amol/L
to >31% at 8 Amol/L; data not shown). In conclusion,
Table 2. Monotherapy versus combined therapy: median effect analysis and CI
A. Comparison of monotherapy (photodynamic therapy or CDDP) versus combined therapy (photodynamic therapy and CDDP) at a
constant light fluence (CI < 1 indicates synergy)
Monotherapy Combined therapy











0 0 100 0.54 — — —
0.18 ND 82 — — —
0.36 1.5 68.5 — — —
0.54 2.5 50 0 1 Additive
0.61 3.0 45 0.25 1.02 Additive
0.73 4.0 36 0.50 0.96 Additive
0.81 1.5 33 1.00 1.04 Additive
0.99 5.0 25 1.50 0.90 Additive
1.08 6.0 20 2.00 0.85 Additive/synergistic
1.25 9.0 12 2.25 0.76 Synergistic
1.44 10.0 7 2.50 0.74 Synergistic
B. Comparison of monotherapy (photodynamic therapy or gemcitabine) versus combined therapy (photodynamic therapy and
gemcitabine) at a constant light fluence (CI = 1 indicates an additive effect)
Monotherapy Combined therapy











0.28 1.5 80 0.28 0 1 —
0.38 2.0 72 2.0 1.03 Additive
0.60 5.5 44 4.0 1.06 Additive
0.80 8.0 30 6.0 0.97 Additive
0.92 12.5 22 8.0 0.99 Additive
C. Comparison of monotherapy (photodynamic therapy or gemcitabine) versus combined therapy (photodynamic therapy and
gemcitabine) at a constant gemcitabine concentration (CI = 1 indicates additivity)
Monotherapy Combined therapy











0.54 4.0 50 0 4.0 1 —
0.65 6.0 41 0.18 1.05 Additive
0.72 6.5 37 0.28 1.01 Additive
0.98 11.0 21 0.36 0.99 Additive
1.2 14.5 15 0.54 0.98 Additive
NOTE: (Dx)1 and (Dx)2 are the doses of light or drug necessary to obtain a given effect when used alone; (D1) and (D2) are the doses of light and drug needed to
obtain the same effect when used in the combination. Column 3 shows the residual cell viability on irradiation at the indicated light fluences [column 1, (Dx)1]
or drug treatment at the indicated concentrations [column 2, (Dx )2], respectively. Columns 4 and 5 (D1 and D2) report the light fluences and drug
concentrations used in combination. Columns 6 and 7 show the CI and the type of effect ensuing from combination. Monotherapy data in Table 2A–C are
taken from Figs. 2 and 3, which provide the relative SD. Combined therapy data were obtained in separate experiments (data not shown).
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it seems that exposure of H1229 cells to sublethal doses of
CDDP for 24 hours was detrimental for cells in S phase and
caused cells to accumulate in G0-G1. This cytofluorimetric
scenario is mirrored by the results of Western blot
experiments.
Gemcitabine. The cytofluorimetric profile of H1299 cells
after incubation for 24 hours with low doses of gemcitabine
indicates a significant accumulation of cells in S phase
(Table 1; Fig. 6), resulting from a massive (50%; trypan blue
assay) loss of cells in the G0-G1 phase. The cell cycle was
profoundly altered when cells were exposed to gemcitabine
(4 nmol/L) for 8, 12, and 24 hours. At 24 hours, most cells
were synchronized in S phase (Table 1). Synchronization in
S phase was sustained for at least 3 hours after drug
removal and the release of cells into fresh medium (data
not shown). The arrest in S phase was not permanent as
indicated by the fact that surviving cells reverted to the
original (control) profile within 24 hours (data not shown).
Cell accumulation in S phase after 24-hour incubation
with gemcitabine, as shown by cytofluorimetry, was also
consistent with an increase in cyclin A expression
(Fig. 5B, lane 2) and in line with previous observations
(23, 24). In conclusion, treatment for 24 hours of H1299 with
sublethal gemcitabine doses was detrimental for cells in the
G0-G1 phase and induced an accumulation of cells in S
phase. This interpretation is supported by both Western
blot experiments and cytofluorimetric profiles. The altered
expression profiles were totally reverted 24 hours after
drug removal.
Photodynamic Therapy. Photodynamic therapy with
2.5 Ag/mL Photofrin (i.e., at a concentration that does not
present ‘‘dark toxicity’’) induced cellular damage propor-
tional to light fluence. Cell injury went from reversible,
with rapid recovery of cellular functions and growth, to
profound and irreversible. At concentrations f10 Ag/mL
Photofrin, photodynamic therapy causes cell death, apo-
ptosis, or necrosis depending on such factors as light
Figure 4. Effect of single versus combined treatment on the viability of
H1299 cells. Viability was evaluated by the trypan blue assay in control
cells, and cells incubated in the dark with Photofrin (2.5 Ag/mL), after
monotherapy with CDDP (2.5 Amol/L), gemcitabine (Gem ; 4 nmol/L), or
photodynamic therapy (0.54 J/cm2), or combined therapy with 2.5 Amol/L
CDDP and photodynamic therapy (0.54 J/cm2) or 4 nmol/L gemcitabine
and photodynamic therapy (0.54 J/cm2). Columns, average of four
determinations (trypan blue exclusion assay); bars, SD.
Figure 5. Protein expression in cells treated with monotherapy or combined therapy. Protein extracts were analyzed 3 or 24 h after cells were placed in fresh
medium after individual or combined treatments (see Fig. 4). A and C, CDDP; B and D, gemcitabine. Actin was always used as loading control. Further
observations: photodynamic therapy increased the expression of p21 (1–3 h), split the Bcl-XL electrophoretic band in a doublet (see also D), and seemed to
destroyBcl-2 (B). Photodynamic therapy also causeda detectable increase inHSP60andHSP70expression. Indeed, although the expression of actin inC is highly
variable, the expressionofHSP70onphotodynamic therapy (aloneor in combination) is clearly increased,whereas thequestionable fadingofBcl-2 is confirmedby
inspection ofB. Gemcitabine significantly affected cyclin A expression (B). Treatment did not affect Bax and caspase-3 expression (C, B andA, D). Photofrin in
the absence of light (dark effect) did not affect cells as shown by two experiments shown in B andD.
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fluence, photosensitizer concentration, and cell type (25).
The Photofrin incubation protocol has also been implicated
in the cell death pathway (26). Although we focused on the
effects of a single light dose (0.54 J/cm2), after 16 hours of
incubation with 2.5 Ag/L Photofrin, few H1299 cells
underwent apoptosis (sub-G1; Fig. 6). Indeed, the expres-
sion of Bax (Fig. 5B and C) and caspase-3 (Fig. 5A and D)
was unchanged 3 and 24 hours after photodynamic
therapy. Differently, Bcl-2 expression was significantly
reduced. This coincides with the finding that some photo-
sensitizers induce Bcl-2 degradation (27). Moreover, Hyper-
icin/photodynamic therapy alters the expression and
function of Bcl-2 and delays the onset of apoptosis (28).
Here, we show that also Photofrin/photodynamic therapy
causes Bcl-2 degradation. This degradation, which can only
be inferred from Fig. 5C (lane 3 ; because of the large actin
control variability), clearly emerges in Fig. 5B (i.e., lane 3).
Finally, Photofrin photodynamic therapy caused changes in
the electrophoretic profile of Bcl-XL as indicated by the
disappearance of the faster-migrating Bcl-XL isoform
(Fig. 5A, lane 3 , and D, lane 3). Pc 4 photodynamic therapy
has been shown to damage Bcl-XL isoforms in several
other human cancer cells (29). Although Hanlon et al. (30)
reported a very important increase in the expressions of
HSP60 and HSP70 proteins, they were only modestly, albeit
clearly, enhanced by photodynamic therapy in our con-
ditions (Fig. 5A, B and C, D, respectively). However,
Hanlon et al. used different cell lines as well as much
higher Photofrin concentrations. Indeed, Photofrin concen-
trations higher than 5 Ag/mL are per se highly toxic for
H1299 cells even in the dark.
We used Western blotting to evaluate changes in protein
expression after monotherapy (i.e., individual drugs or
photodynamic therapy) and after combined treatments
(i.e., each drug + photodynamic therapy). It is noteworthy
that with time most protein expression profiles tended to
revert to their original qualitative and quantitative patterns
(Fig. 5A–D). The apparent ‘‘increase’’ in cyclin A expres-
sion (Fig. 5C, lanes 5 –7) may represent an experimental
artifact given the large variability of the actin control. As
stated, the expression of HSP60 and HSP70 proteins was
enhanced after 24 hours albeit to a lesser extent versus
cyclin A (Fig. 5A, C, and D). The cell cycle patterns after
combined therapy (Fig. 6E and F) are not in disagreement
with the protein expression profiling data.
Figure 6 is representative of various experiments con-
cerning the effects of combined treatment. Within 24 hours,
2.5 Amol/L CDDP killedf50% of cells, most of which were
in S phase (Fig. 6B). At variance, photodynamic therapy
(0.54 J/cm2) eliminated mainly G0-G1 cells (Fig. 6D), and
most of the remaining cells were in S phase. In conclusion,
CDDP, at a low concentration, killed cells in S phase, and
surviving cells occurred mainly in G0-G1, a phase in which
cells are susceptible to photodynamic therapy (Table 2A).
Gemcitabine alone, at a concentration as low as 4 nmol/L,
killed f50% of cells (most of which were in G0-G1 phase)
and induced a pronounced accumulation of cells in S phase
(Fig. 6C). It seems that gemcitabine at this concentration
enhances photodynamic therapy cytotoxicity, but to a much
lesser extent than CDDP, and the effect is essentially additive
(Table 2B and C). In controls, 44.2% were in G0-G1, 44.6%
were in S, and 11.2% were in G2-M. After photodynamic
Figure 6. Representative experiments
depicting the cell cycle distribution of
H1299 cells as measured by flow cytometric
analysis of DNA content before (A, controls)
and after treatment with CDDP (B), gemci-
tabine (C), photodynamic therapy alone (D),
or in sequential combination (E and F). In
these cases, cells were analyzed 24 h after
photodynamic therapy. The FACScan soft-
ware assigns apoptotic cells and large cell
debris to sub-G1 phase. Gray histograms,
G0-G1 and G2-M phases; dashed histo-
grams, S phase.
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therapy (0.54 J/cm2) or 24 hours of incubation with CDDP
(2.5 Amol/L) or gemcitabine (4 nmol/L; all conditions that
killf50% of cells), 31.2%, 76.1%, and 18.0% of cells were in
G0-G1, 56.7%, 10.5%, and 82.0% were in S, and 12.1%, 13.4%,
andf0% were in G2-M, respectively. Hence, photodynamic
therapy and gemcitabine preferentially damage cells in
G0-G1, whereas CDDP targets cells in S phase. In conclusion,
it seems that the targeting of cells in different phases results
in an accumulation of death signals caused separately and
independently by photodynamic therapy and a suitable
cytotoxic drug.
Photodynamic therapy is a well-established stand-alone
therapy (9) in which the photosensitizer can be administered
by i.v. injection or applied on the skin and selectively targets
cancer cells. Its effectiveness increases when combined with
other therapeutic measures. Here, we describe a way to
exploit mutual reinforcement of two independent therapeu-
tic modalities: Photofrin/photodynamic therapy and che-
motherapy. Photofrin and porphyrin derivatives, in general,
are the photosensitizers most widely used in photodynamic
therapy. At variance with gemcitabine, which to our
knowledge has never been used with Photofrin/photody-
namic therapy, CDDP has been used in combination with
various photosensitizers, including porphyrin derivatives
(11, 31–35). However, previous studies were mainly
descriptive and were limited to observations about the
effects exerted on cell mortality. No reasons were advanced
to account for the greater efficacy of combined treatment, nor
did those studies report changes in protein expression and
related cell cycle changes. Our study shows that doses of
CDDP or gemcitabine and light/Photofrin that were
partially effective in killing H1299 cells when given singly
were remarkably more effective when used in combination.
These effects span from additive to synergistic. Additivity
occurred with both drugs, but the effect was synergistic
when the drug (CDDP) exerted its activity disjointed, in
terms of cell cycle, from those of photodynamic therapy.
Under the conditions we used, not all metastatic cells were
killed. However, preincubation of H1299 cells with the low
CDDP dose (2.5 Amol/L) followed by their exposure to a
light fluence only 1.5-fold higher (i.e.,f0.80 J/cm2) than that
used in most experiments described herein (f0.54 J/cm2)
resulted in the rapid death of all cells.
In conclusion, selectively localized photosensitizers and
appropriate doses of light combined with low doses of
chemotherapeutic drugs represent a promising treatment
strategy for cancer. In principle, combinations of photody-
namic therapy and drugs would not only destroy cancer
cells more efficiently but would also reduce the noxious
side effects of chemotherapy.
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